At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that ...

Sibeprenlimab gains accelerated approval from the FDA for IgA nephropathy, showing significant proteinuria reduction and ...

Get the latest on Vera Therapeutics, Inc., FDA progress for atacicept, and IgA nephropathy drug competition. Click to what to ...

In this MedPage Today video, Sayna Norouzi, MD, of the Loma Linda University Medical Center in California, offers practical ...

Dr Pietro A. Canetta illustrates recent advances in IgA nephropathy and focal segmental glomerulosclerosis (FSGS) with two ...

Vertex Pharmaceuticals recently reported positive clinical trial data for povetacicept in IgA nephropathy and primary ...

"Renalys eyes Japanese Filspari approval on Phase III IgA nephropathy win" was originally created and published by Clinical ...

The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to ...

KDIGO updated treatment guidelines for two kidney diseases, which could improve patient care and outcomes according to ...

At the one-year follow-up, the annual change in eGFR was −1.16 mL/min/1.73 m² in the unvaccinated group, −1.03 in the ...

Immunoglobulin A (IgA) nephropathy is an autoimmune condition that causes inflammation and damage in your kidneys, which may lead to kidney failure over time. IgA nephropathy develops when IgA builds ...

IgA nephropathy is hard to predict. But there’s one thing experts know. People with strong emotional and social support systems tend do better in the long run. And it’s best to live your life to the ...